| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 16 | 2024 | 373 | 5.970 |
Why?
|
| Energy Metabolism | 49 | 2025 | 809 | 4.830 |
Why?
|
| Body Composition | 44 | 2024 | 564 | 3.870 |
Why?
|
| Antiviral Agents | 17 | 2024 | 822 | 3.760 |
Why?
|
| Water | 18 | 2025 | 198 | 3.510 |
Why?
|
| Cost-Benefit Analysis | 25 | 2025 | 567 | 3.360 |
Why?
|
| Hepatitis B, Chronic | 5 | 2025 | 86 | 3.310 |
Why?
|
| Oxygen Isotopes | 16 | 2024 | 36 | 2.700 |
Why?
|
| Deuterium | 19 | 2024 | 109 | 2.430 |
Why?
|
| Adipose Tissue | 18 | 2022 | 498 | 2.320 |
Why?
|
| Hepatitis C | 8 | 2025 | 388 | 2.180 |
Why?
|
| Liver Neoplasms | 9 | 2024 | 1409 | 2.140 |
Why?
|
| Ontario | 19 | 2025 | 91 | 2.130 |
Why?
|
| Isoflavones | 7 | 2013 | 46 | 2.110 |
Why?
|
| Hepatitis B | 4 | 2024 | 172 | 2.020 |
Why?
|
| Canada | 16 | 2025 | 344 | 1.920 |
Why?
|
| Carcinoma, Hepatocellular | 6 | 2024 | 999 | 1.850 |
Why?
|
| Quality of Life | 9 | 2025 | 2131 | 1.820 |
Why?
|
| Body Water | 22 | 2025 | 90 | 1.570 |
Why?
|
| Self Concept | 4 | 2016 | 160 | 1.540 |
Why?
|
| Obesity | 19 | 2025 | 2409 | 1.530 |
Why?
|
| Health Care Costs | 11 | 2025 | 404 | 1.530 |
Why?
|
| Hepacivirus | 9 | 2024 | 273 | 1.520 |
Why?
|
| Exercise | 14 | 2023 | 879 | 1.450 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2024 | 379 | 1.430 |
Why?
|
| Health Expenditures | 2 | 2023 | 116 | 1.420 |
Why?
|
| Humans | 205 | 2025 | 133809 | 1.390 |
Why?
|
| Quality-Adjusted Life Years | 11 | 2025 | 129 | 1.360 |
Why?
|
| Mass Screening | 8 | 2024 | 832 | 1.320 |
Why?
|
| Body Mass Index | 22 | 2025 | 1708 | 1.300 |
Why?
|
| Body Weight | 20 | 2021 | 1034 | 1.290 |
Why?
|
| Adult | 89 | 2025 | 31928 | 1.260 |
Why?
|
| Female | 137 | 2025 | 71587 | 1.240 |
Why?
|
| Energy Intake | 20 | 2025 | 519 | 1.220 |
Why?
|
| Middle Aged | 66 | 2025 | 29350 | 1.210 |
Why?
|
| Male | 110 | 2025 | 65830 | 1.160 |
Why?
|
| Liver Cirrhosis | 7 | 2024 | 933 | 1.160 |
Why?
|
| Hemophilia A | 2 | 2025 | 23 | 1.130 |
Why?
|
| Menopause | 3 | 2013 | 88 | 1.120 |
Why?
|
| beta-Glucans | 3 | 2013 | 20 | 1.090 |
Why?
|
| Proton Therapy | 6 | 2024 | 149 | 1.060 |
Why?
|
| Dietary Supplements | 7 | 2021 | 498 | 1.050 |
Why?
|
| Models, Economic | 3 | 2025 | 55 | 1.010 |
Why?
|
| Lung Neoplasms | 5 | 2024 | 1792 | 1.000 |
Why?
|
| Factor VIII | 2 | 2025 | 48 | 0.980 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2025 | 149 | 0.970 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2025 | 35 | 0.960 |
Why?
|
| Postmenopause | 3 | 2010 | 156 | 0.930 |
Why?
|
| Feasibility Studies | 3 | 2024 | 818 | 0.910 |
Why?
|
| Breast Neoplasms | 12 | 2024 | 2760 | 0.890 |
Why?
|
| Minority Groups | 5 | 2017 | 255 | 0.890 |
Why?
|
| Indicator Dilution Techniques | 6 | 2025 | 25 | 0.880 |
Why?
|
| Early Detection of Cancer | 4 | 2025 | 413 | 0.870 |
Why?
|
| Weight Loss | 8 | 2024 | 516 | 0.860 |
Why?
|
| Weight Reduction Programs | 3 | 2016 | 60 | 0.860 |
Why?
|
| Deuterium Oxide | 6 | 2024 | 17 | 0.860 |
Why?
|
| Aged | 40 | 2025 | 21701 | 0.820 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2024 | 610 | 0.810 |
Why?
|
| Patient Preference | 2 | 2021 | 135 | 0.800 |
Why?
|
| Drug Costs | 2 | 2019 | 67 | 0.770 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 8 | 2024 | 81 | 0.770 |
Why?
|
| Camping | 3 | 2016 | 14 | 0.760 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2022 | 45 | 0.760 |
Why?
|
| Radium | 2 | 2022 | 5 | 0.750 |
Why?
|
| Diet | 8 | 2019 | 1196 | 0.750 |
Why?
|
| Young Adult | 29 | 2025 | 9902 | 0.730 |
Why?
|
| Anthropometry | 6 | 2024 | 202 | 0.720 |
Why?
|
| Absorptiometry, Photon | 8 | 2022 | 205 | 0.690 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2021 | 97 | 0.690 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2025 | 884 | 0.680 |
Why?
|
| Adolescent | 35 | 2025 | 20542 | 0.680 |
Why?
|
| Prevalence | 8 | 2025 | 2655 | 0.680 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2022 | 98 | 0.670 |
Why?
|
| Hepatitis B virus | 3 | 2024 | 142 | 0.670 |
Why?
|
| Decision Making | 1 | 2025 | 696 | 0.660 |
Why?
|
| Plant Extracts | 2 | 2012 | 140 | 0.660 |
Why?
|
| Preimplantation Diagnosis | 1 | 2020 | 26 | 0.650 |
Why?
|
| Cost of Illness | 3 | 2021 | 275 | 0.650 |
Why?
|
| Bone Density | 6 | 2009 | 370 | 0.650 |
Why?
|
| Cross-Sectional Studies | 16 | 2025 | 3738 | 0.640 |
Why?
|
| Aged, 80 and over | 15 | 2025 | 7194 | 0.620 |
Why?
|
| Mass Spectrometry | 8 | 2015 | 371 | 0.620 |
Why?
|
| Diet, Carbohydrate-Restricted | 5 | 2024 | 29 | 0.610 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2023 | 203 | 0.610 |
Why?
|
| Chemistry Techniques, Analytical | 1 | 2018 | 8 | 0.610 |
Why?
|
| Pancreatic Neoplasms | 1 | 2025 | 734 | 0.610 |
Why?
|
| Basal Metabolism | 11 | 2023 | 98 | 0.590 |
Why?
|
| Cohort Studies | 13 | 2024 | 5175 | 0.580 |
Why?
|
| Isotope Labeling | 8 | 2022 | 106 | 0.570 |
Why?
|
| Mastectomy | 5 | 2023 | 81 | 0.570 |
Why?
|
| Dementia | 1 | 2023 | 485 | 0.560 |
Why?
|
| Hydrogen | 6 | 2012 | 41 | 0.560 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2023 | 1311 | 0.550 |
Why?
|
| Retrospective Studies | 20 | 2025 | 17457 | 0.540 |
Why?
|
| Emigrants and Immigrants | 2 | 2024 | 153 | 0.540 |
Why?
|
| Prostatic Neoplasms | 5 | 2024 | 1622 | 0.530 |
Why?
|
| Head and Neck Neoplasms | 3 | 2017 | 698 | 0.530 |
Why?
|
| Bone Neoplasms | 2 | 2022 | 447 | 0.530 |
Why?
|
| Infant Nutritional Physiological Phenomena | 4 | 2015 | 195 | 0.520 |
Why?
|
| Milk, Human | 7 | 2015 | 311 | 0.520 |
Why?
|
| Child | 31 | 2025 | 25743 | 0.510 |
Why?
|
| British Columbia | 4 | 2024 | 11 | 0.500 |
Why?
|
| Community Health Services | 2 | 2016 | 92 | 0.500 |
Why?
|
| Brachytherapy | 3 | 2024 | 92 | 0.500 |
Why?
|
| Reproducibility of Results | 14 | 2017 | 3057 | 0.500 |
Why?
|
| Breast Feeding | 6 | 2019 | 243 | 0.490 |
Why?
|
| Overweight | 6 | 2018 | 384 | 0.490 |
Why?
|
| Urinalysis | 1 | 2015 | 55 | 0.490 |
Why?
|
| Kidney Failure, Chronic | 3 | 2013 | 911 | 0.480 |
Why?
|
| Body Fat Distribution | 1 | 2015 | 31 | 0.470 |
Why?
|
| Antineoplastic Agents | 4 | 2019 | 1849 | 0.470 |
Why?
|
| Diet, Reducing | 2 | 2020 | 93 | 0.470 |
Why?
|
| Treatment Outcome | 16 | 2024 | 12994 | 0.470 |
Why?
|
| Self Report | 6 | 2025 | 551 | 0.460 |
Why?
|
| Health Promotion | 2 | 2016 | 402 | 0.450 |
Why?
|
| Surveys and Questionnaires | 7 | 2023 | 3985 | 0.450 |
Why?
|
| Sleep | 3 | 2016 | 369 | 0.450 |
Why?
|
| Osteoporosis, Postmenopausal | 2 | 2011 | 31 | 0.440 |
Why?
|
| Organs at Risk | 7 | 2024 | 37 | 0.440 |
Why?
|
| Infant, Newborn | 27 | 2023 | 8582 | 0.430 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 1353 | 0.420 |
Why?
|
| Antibodies, Bispecific | 2 | 2025 | 51 | 0.410 |
Why?
|
| Nephrotic Syndrome | 1 | 2013 | 52 | 0.410 |
Why?
|
| Developed Countries | 2 | 2024 | 45 | 0.410 |
Why?
|
| Phantoms, Imaging | 3 | 2024 | 141 | 0.400 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2012 | 95 | 0.390 |
Why?
|
| Child, Preschool | 21 | 2025 | 14787 | 0.370 |
Why?
|
| Nutritional Status | 2 | 2015 | 328 | 0.370 |
Why?
|
| Artificial Intelligence | 3 | 2024 | 298 | 0.370 |
Why?
|
| Incidence | 6 | 2024 | 3393 | 0.370 |
Why?
|
| Phytoestrogens | 2 | 2010 | 16 | 0.360 |
Why?
|
| Peritoneal Dialysis | 2 | 2012 | 131 | 0.360 |
Why?
|
| Socioeconomic Factors | 3 | 2025 | 919 | 0.360 |
Why?
|
| Models, Biological | 13 | 2014 | 1535 | 0.360 |
Why?
|
| Blood Urea Nitrogen | 1 | 2010 | 77 | 0.350 |
Why?
|
| Nutritional Requirements | 7 | 2018 | 181 | 0.350 |
Why?
|
| Breast Implants | 2 | 2021 | 31 | 0.350 |
Why?
|
| Age Factors | 7 | 2024 | 2978 | 0.350 |
Why?
|
| Mammaplasty | 3 | 2021 | 55 | 0.350 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2021 | 102 | 0.340 |
Why?
|
| Models, Theoretical | 2 | 2025 | 398 | 0.340 |
Why?
|
| Pregnancy | 17 | 2022 | 7513 | 0.340 |
Why?
|
| Blood Pressure | 3 | 2017 | 1410 | 0.330 |
Why?
|
| Photons | 2 | 2024 | 53 | 0.330 |
Why?
|
| Liver Transplantation | 3 | 2021 | 1124 | 0.330 |
Why?
|
| Child Nutritional Physiological Phenomena | 3 | 2016 | 174 | 0.330 |
Why?
|
| Endometrial Neoplasms | 1 | 2011 | 114 | 0.330 |
Why?
|
| Longitudinal Studies | 8 | 2023 | 1489 | 0.330 |
Why?
|
| Behavior Therapy | 1 | 2012 | 268 | 0.310 |
Why?
|
| Hospitals | 2 | 2023 | 428 | 0.310 |
Why?
|
| Vitamin B Complex | 1 | 2009 | 45 | 0.310 |
Why?
|
| Adiposity | 3 | 2021 | 209 | 0.310 |
Why?
|
| Nitric Oxide | 1 | 2012 | 490 | 0.310 |
Why?
|
| Substance-Related Disorders | 2 | 2023 | 490 | 0.300 |
Why?
|
| Infant | 22 | 2022 | 13148 | 0.290 |
Why?
|
| Program Evaluation | 6 | 2016 | 455 | 0.290 |
Why?
|
| Sex Factors | 6 | 2017 | 1384 | 0.290 |
Why?
|
| Mammography | 1 | 2009 | 132 | 0.290 |
Why?
|
| Breast | 2 | 2009 | 218 | 0.290 |
Why?
|
| Radiotherapy Dosage | 7 | 2024 | 224 | 0.290 |
Why?
|
| Double-Blind Method | 5 | 2013 | 1669 | 0.280 |
Why?
|
| Ribavirin | 2 | 2020 | 89 | 0.280 |
Why?
|
| Extracellular Space | 3 | 2000 | 90 | 0.280 |
Why?
|
| Life Style | 3 | 2025 | 454 | 0.270 |
Why?
|
| Pregnancy, Twin | 2 | 2018 | 182 | 0.270 |
Why?
|
| Insulin | 4 | 2019 | 1246 | 0.270 |
Why?
|
| Disease Eradication | 2 | 2024 | 39 | 0.270 |
Why?
|
| Mastectomy, Segmental | 2 | 2024 | 40 | 0.270 |
Why?
|
| Placebos | 4 | 2013 | 240 | 0.270 |
Why?
|
| Proteins | 6 | 2018 | 1087 | 0.260 |
Why?
|
| Dietary Proteins | 5 | 2015 | 255 | 0.260 |
Why?
|
| Bromides | 2 | 2000 | 4 | 0.250 |
Why?
|
| Prognosis | 7 | 2019 | 5068 | 0.250 |
Why?
|
| Diet Surveys | 2 | 2016 | 103 | 0.240 |
Why?
|
| Membrane Proteins | 1 | 2013 | 1606 | 0.240 |
Why?
|
| Puberty | 2 | 2023 | 103 | 0.240 |
Why?
|
| Linear Energy Transfer | 2 | 2024 | 9 | 0.240 |
Why?
|
| Half-Life | 2 | 2025 | 160 | 0.240 |
Why?
|
| Carbazoles | 1 | 2024 | 35 | 0.230 |
Why?
|
| Calibration | 3 | 2022 | 100 | 0.230 |
Why?
|
| Athletes | 1 | 2025 | 76 | 0.230 |
Why?
|
| Rectum | 3 | 2024 | 113 | 0.230 |
Why?
|
| Disease Progression | 4 | 2021 | 2240 | 0.220 |
Why?
|
| Quebec | 1 | 2024 | 7 | 0.220 |
Why?
|
| Urine | 3 | 2012 | 83 | 0.220 |
Why?
|
| Vaccination | 2 | 2023 | 1011 | 0.220 |
Why?
|
| Plethysmography | 3 | 2012 | 36 | 0.220 |
Why?
|
| World Health Organization | 1 | 2024 | 117 | 0.220 |
Why?
|
| Models, Statistical | 3 | 2018 | 505 | 0.220 |
Why?
|
| Mutation | 2 | 2020 | 6292 | 0.220 |
Why?
|
| Prospective Studies | 10 | 2023 | 6660 | 0.220 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2024 | 73 | 0.220 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 1 | 2003 | 3 | 0.210 |
Why?
|
| Radiation Oncology | 1 | 2024 | 28 | 0.210 |
Why?
|
| School Health Services | 2 | 2016 | 100 | 0.210 |
Why?
|
| Propensity Score | 1 | 2025 | 258 | 0.210 |
Why?
|
| Motor Activity | 5 | 2014 | 537 | 0.210 |
Why?
|
| Liver | 4 | 2019 | 1866 | 0.210 |
Why?
|
| Transients and Migrants | 1 | 2003 | 24 | 0.210 |
Why?
|
| Neoplasms | 4 | 2023 | 3023 | 0.210 |
Why?
|
| Dietary Carbohydrates | 3 | 2020 | 121 | 0.210 |
Why?
|
| Protons | 2 | 2024 | 98 | 0.210 |
Why?
|
| Carbohydrates | 2 | 2019 | 38 | 0.200 |
Why?
|
| Infant, Premature | 5 | 2012 | 859 | 0.200 |
Why?
|
| Drinking | 1 | 2022 | 35 | 0.200 |
Why?
|
| Health Services | 1 | 2023 | 73 | 0.200 |
Why?
|
| Piperidines | 1 | 2024 | 238 | 0.200 |
Why?
|
| Survivors | 2 | 2015 | 361 | 0.200 |
Why?
|
| Four-Dimensional Computed Tomography | 2 | 2019 | 10 | 0.200 |
Why?
|
| Salvage Therapy | 1 | 2004 | 202 | 0.190 |
Why?
|
| Regression Analysis | 6 | 2016 | 830 | 0.190 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2015 | 251 | 0.190 |
Why?
|
| Birth Weight | 4 | 2018 | 352 | 0.190 |
Why?
|
| Hepatitis B Vaccines | 1 | 2022 | 45 | 0.190 |
Why?
|
| Time Factors | 6 | 2019 | 6584 | 0.190 |
Why?
|
| Hypocotyl | 2 | 2012 | 7 | 0.190 |
Why?
|
| Pregnancy Trimesters | 2 | 2018 | 34 | 0.190 |
Why?
|
| Hong Kong | 1 | 2021 | 16 | 0.190 |
Why?
|
| Linear Models | 7 | 2018 | 723 | 0.190 |
Why?
|
| Emigration and Immigration | 1 | 2022 | 82 | 0.190 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 149 | 0.190 |
Why?
|
| Heart Failure, Systolic | 1 | 2022 | 36 | 0.190 |
Why?
|
| Social Class | 3 | 2022 | 204 | 0.190 |
Why?
|
| Poverty | 2 | 2016 | 435 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2019 | 1200 | 0.180 |
Why?
|
| Sexual Behavior | 1 | 2023 | 250 | 0.180 |
Why?
|
| Lasers | 1 | 2022 | 118 | 0.180 |
Why?
|
| Ultrasonography | 2 | 2018 | 996 | 0.180 |
Why?
|
| Risk Factors | 9 | 2020 | 11071 | 0.180 |
Why?
|
| Malnutrition | 2 | 2021 | 218 | 0.180 |
Why?
|
| Residence Characteristics | 2 | 2014 | 292 | 0.180 |
Why?
|
| Databases, Factual | 3 | 2022 | 1244 | 0.180 |
Why?
|
| Texas | 4 | 2014 | 3683 | 0.180 |
Why?
|
| Sofosbuvir | 1 | 2020 | 21 | 0.180 |
Why?
|
| Income | 1 | 2021 | 141 | 0.170 |
Why?
|
| Body Fluid Compartments | 2 | 2018 | 19 | 0.170 |
Why?
|
| Eating | 2 | 2017 | 387 | 0.170 |
Why?
|
| Breast Implantation | 1 | 2020 | 10 | 0.170 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2020 | 34 | 0.170 |
Why?
|
| Urban Population | 4 | 2014 | 240 | 0.170 |
Why?
|
| Health Status | 2 | 2019 | 412 | 0.170 |
Why?
|
| Carbamates | 1 | 2020 | 68 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 553 | 0.170 |
Why?
|
| Plasma Volume | 1 | 2000 | 15 | 0.170 |
Why?
|
| Health Resources | 1 | 2021 | 125 | 0.170 |
Why?
|
| Women's Health | 2 | 2012 | 150 | 0.170 |
Why?
|
| Accelerometry | 3 | 2018 | 64 | 0.170 |
Why?
|
| Pediatric Obesity | 2 | 2016 | 403 | 0.170 |
Why?
|
| Kidney Neoplasms | 2 | 2015 | 460 | 0.170 |
Why?
|
| Breeding | 1 | 1999 | 23 | 0.160 |
Why?
|
| International Agencies | 1 | 2019 | 31 | 0.160 |
Why?
|
| History, 20th Century | 2 | 2018 | 397 | 0.160 |
Why?
|
| Water Supply | 1 | 2019 | 27 | 0.160 |
Why?
|
| Nutritive Value | 2 | 2012 | 93 | 0.160 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2022 | 253 | 0.160 |
Why?
|
| BRCA1 Protein | 1 | 2020 | 82 | 0.160 |
Why?
|
| Community Health Centers | 1 | 2019 | 41 | 0.160 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 1999 | 35 | 0.160 |
Why?
|
| Ovariectomy | 1 | 2000 | 188 | 0.160 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2024 | 623 | 0.160 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2019 | 42 | 0.160 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2023 | 168 | 0.160 |
Why?
|
| Prosthesis Failure | 1 | 2020 | 168 | 0.160 |
Why?
|
| Minerals | 2 | 1998 | 60 | 0.160 |
Why?
|
| Phenylurea Compounds | 1 | 2019 | 56 | 0.160 |
Why?
|
| United States | 6 | 2023 | 11663 | 0.160 |
Why?
|
| Science | 1 | 2019 | 37 | 0.160 |
Why?
|
| Sheep | 1 | 1999 | 237 | 0.160 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1153 | 0.160 |
Why?
|
| Lymphatic Metastasis | 2 | 2017 | 453 | 0.150 |
Why?
|
| Weight Gain | 7 | 2022 | 414 | 0.150 |
Why?
|
| Algorithms | 3 | 2024 | 1728 | 0.150 |
Why?
|
| Literature, Modern | 1 | 2018 | 3 | 0.150 |
Why?
|
| Quinolines | 1 | 2019 | 112 | 0.150 |
Why?
|
| Survival Rate | 4 | 2017 | 2201 | 0.150 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 238 | 0.150 |
Why?
|
| Twins, Dizygotic | 1 | 2018 | 47 | 0.150 |
Why?
|
| Combined Modality Therapy | 3 | 2017 | 1307 | 0.150 |
Why?
|
| Fertilization in Vitro | 1 | 2020 | 161 | 0.150 |
Why?
|
| HIV | 1 | 2019 | 195 | 0.150 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 2082 | 0.150 |
Why?
|
| Movement | 1 | 2019 | 180 | 0.140 |
Why?
|
| Body Height | 2 | 2018 | 231 | 0.140 |
Why?
|
| Genotype | 3 | 2020 | 2807 | 0.140 |
Why?
|
| RNA, Viral | 3 | 2023 | 562 | 0.140 |
Why?
|
| Health Education | 3 | 2009 | 228 | 0.140 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1999 | 352 | 0.140 |
Why?
|
| Cholesterol | 3 | 1995 | 574 | 0.140 |
Why?
|
| Markov Chains | 2 | 2019 | 99 | 0.140 |
Why?
|
| Prostatectomy | 3 | 2023 | 357 | 0.140 |
Why?
|
| Aging | 2 | 2022 | 1304 | 0.140 |
Why?
|
| Potassium, Dietary | 1 | 2017 | 13 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 291 | 0.140 |
Why?
|
| Sodium, Dietary | 1 | 2017 | 37 | 0.140 |
Why?
|
| Fetal Development | 1 | 2018 | 133 | 0.140 |
Why?
|
| Analysis of Variance | 6 | 2004 | 1046 | 0.130 |
Why?
|
| Heart Failure | 2 | 2022 | 2399 | 0.130 |
Why?
|
| Skinfold Thickness | 2 | 2015 | 33 | 0.130 |
Why?
|
| Reproduction | 3 | 2023 | 245 | 0.130 |
Why?
|
| Photography | 1 | 2017 | 101 | 0.130 |
Why?
|
| Sugars | 1 | 2016 | 17 | 0.130 |
Why?
|
| Tumor Hypoxia | 1 | 2016 | 6 | 0.130 |
Why?
|
| Biological Availability | 2 | 2011 | 152 | 0.130 |
Why?
|
| Caloric Restriction | 1 | 2017 | 88 | 0.130 |
Why?
|
| Carbon Dioxide | 11 | 1994 | 289 | 0.130 |
Why?
|
| Food | 3 | 2017 | 140 | 0.130 |
Why?
|
| Dietary Sucrose | 1 | 2016 | 42 | 0.130 |
Why?
|
| Medical Oncology | 1 | 2018 | 244 | 0.130 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 5503 | 0.130 |
Why?
|
| Chromatography, Ion Exchange | 2 | 2000 | 67 | 0.120 |
Why?
|
| Seasons | 2 | 2013 | 330 | 0.120 |
Why?
|
| Caregivers | 1 | 2021 | 585 | 0.120 |
Why?
|
| Nitrogen | 2 | 2015 | 148 | 0.120 |
Why?
|
| Calorimetry, Indirect | 4 | 2021 | 61 | 0.120 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 1 | 2015 | 33 | 0.120 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 1478 | 0.120 |
Why?
|
| Pandemics | 1 | 2023 | 1195 | 0.120 |
Why?
|
| Soybean Proteins | 2 | 2011 | 18 | 0.120 |
Why?
|
| Sri Lanka | 1 | 2015 | 11 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 679 | 0.120 |
Why?
|
| Child Health Services | 1 | 2016 | 88 | 0.120 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2015 | 71 | 0.120 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 265 | 0.120 |
Why?
|
| Premedication | 1 | 2015 | 42 | 0.120 |
Why?
|
| Febrile Neutropenia | 1 | 2015 | 15 | 0.120 |
Why?
|
| RNA, Neoplasm | 1 | 2015 | 144 | 0.120 |
Why?
|
| Biological Specimen Banks | 1 | 2015 | 54 | 0.120 |
Why?
|
| Facial Neoplasms | 1 | 2015 | 22 | 0.120 |
Why?
|
| Hemangiosarcoma | 1 | 2015 | 47 | 0.110 |
Why?
|
| Alpha Particles | 1 | 2014 | 1 | 0.110 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 153 | 0.110 |
Why?
|
| Scalp | 1 | 2015 | 59 | 0.110 |
Why?
|
| Papillomavirus Vaccines | 1 | 2016 | 106 | 0.110 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2015 | 93 | 0.110 |
Why?
|
| ErbB Receptors | 1 | 2016 | 304 | 0.110 |
Why?
|
| Recommended Dietary Allowances | 1 | 2014 | 24 | 0.110 |
Why?
|
| Lung | 2 | 2019 | 1555 | 0.110 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 1388 | 0.110 |
Why?
|
| Nose Neoplasms | 1 | 2014 | 34 | 0.110 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 748 | 0.110 |
Why?
|
| Adaptation, Physiological | 2 | 2015 | 293 | 0.110 |
Why?
|
| Biomarkers | 4 | 2017 | 3423 | 0.110 |
Why?
|
| Animals | 12 | 2022 | 36364 | 0.110 |
Why?
|
| New Zealand | 1 | 2013 | 61 | 0.110 |
Why?
|
| Founder Effect | 1 | 2013 | 34 | 0.110 |
Why?
|
| Heart Rate | 3 | 2014 | 601 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2017 | 1596 | 0.100 |
Why?
|
| Interferon-alpha | 1 | 2015 | 248 | 0.100 |
Why?
|
| Heart-Assist Devices | 1 | 2022 | 1075 | 0.100 |
Why?
|
| Genetic Testing | 1 | 2020 | 1093 | 0.100 |
Why?
|
| Bariatric Surgery | 1 | 2015 | 142 | 0.100 |
Why?
|
| Platinum | 1 | 2012 | 13 | 0.100 |
Why?
|
| Gases | 1 | 2012 | 20 | 0.100 |
Why?
|
| Research Design | 3 | 2024 | 755 | 0.100 |
Why?
|
| Oxygen | 3 | 2016 | 580 | 0.100 |
Why?
|
| Disease-Free Survival | 4 | 2016 | 969 | 0.100 |
Why?
|
| Cats | 1 | 2012 | 126 | 0.100 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 267 | 0.100 |
Why?
|
| Hypercholesterolemia | 1 | 1995 | 234 | 0.100 |
Why?
|
| Catalysis | 1 | 2012 | 137 | 0.100 |
Why?
|
| Diet, Fat-Restricted | 1 | 2012 | 41 | 0.100 |
Why?
|
| Heart Valve Diseases | 1 | 2014 | 181 | 0.100 |
Why?
|
| Obesity, Morbid | 1 | 2015 | 212 | 0.100 |
Why?
|
| Waiting Lists | 1 | 2014 | 244 | 0.100 |
Why?
|
| Infant Food | 5 | 2007 | 81 | 0.090 |
Why?
|
| HIV Infections | 2 | 2019 | 2066 | 0.090 |
Why?
|
| Prostate-Specific Antigen | 2 | 2022 | 272 | 0.090 |
Why?
|
| Renal Replacement Therapy | 1 | 2013 | 155 | 0.090 |
Why?
|
| Zinc | 1 | 2012 | 141 | 0.090 |
Why?
|
| Equol | 1 | 2011 | 3 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2024 | 2196 | 0.090 |
Why?
|
| Histones | 1 | 2015 | 569 | 0.090 |
Why?
|
| Physical Fitness | 2 | 2009 | 94 | 0.090 |
Why?
|
| Tritium | 1 | 1991 | 171 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 3064 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2016 | 398 | 0.090 |
Why?
|
| Aortic Valve | 1 | 2014 | 454 | 0.090 |
Why?
|
| Treatment Failure | 1 | 2012 | 361 | 0.090 |
Why?
|
| Lactation | 4 | 1997 | 201 | 0.080 |
Why?
|
| Serologic Tests | 2 | 2021 | 131 | 0.080 |
Why?
|
| Endometrium | 1 | 2013 | 287 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 873 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 1487 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 650 | 0.080 |
Why?
|
| Thiamine | 1 | 2009 | 10 | 0.080 |
Why?
|
| Risk | 1 | 2012 | 831 | 0.080 |
Why?
|
| Electric Conductivity | 4 | 2002 | 90 | 0.080 |
Why?
|
| Phenotype | 2 | 2023 | 4530 | 0.080 |
Why?
|
| Riboflavin | 1 | 2009 | 41 | 0.080 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2014 | 451 | 0.080 |
Why?
|
| Vitamin B 12 | 1 | 2009 | 63 | 0.080 |
Why?
|
| Sex Characteristics | 2 | 2022 | 335 | 0.080 |
Why?
|
| Carbon Isotopes | 5 | 1996 | 279 | 0.080 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2009 | 195 | 0.080 |
Why?
|
| Seroepidemiologic Studies | 2 | 2020 | 145 | 0.080 |
Why?
|
| Gestational Age | 4 | 2018 | 1215 | 0.070 |
Why?
|
| Nutrition Surveys | 2 | 2025 | 313 | 0.070 |
Why?
|
| Vitamin D | 1 | 2009 | 177 | 0.070 |
Why?
|
| Lactose | 2 | 2005 | 56 | 0.070 |
Why?
|
| Urban Health Services | 1 | 2007 | 22 | 0.070 |
Why?
|
| Software | 3 | 2018 | 737 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 906 | 0.070 |
Why?
|
| Guanidines | 1 | 1987 | 26 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 2123 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 480 | 0.070 |
Why?
|
| Mathematics | 7 | 2003 | 97 | 0.070 |
Why?
|
| Reference Values | 3 | 2018 | 744 | 0.070 |
Why?
|
| Bias | 2 | 2015 | 147 | 0.070 |
Why?
|
| Blood Chemical Analysis | 1 | 1987 | 85 | 0.070 |
Why?
|
| Body Fluids | 1 | 1987 | 49 | 0.070 |
Why?
|
| Electroacupuncture | 1 | 2006 | 9 | 0.060 |
Why?
|
| Gastric Emptying | 1 | 2006 | 78 | 0.060 |
Why?
|
| Saliva | 1 | 1987 | 132 | 0.060 |
Why?
|
| Cognition | 1 | 2012 | 815 | 0.060 |
Why?
|
| Health Behavior | 1 | 2009 | 402 | 0.060 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2006 | 24 | 0.060 |
Why?
|
| Carbon | 2 | 1985 | 99 | 0.060 |
Why?
|
| HIV Antibodies | 1 | 2006 | 71 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 2 | 2021 | 429 | 0.060 |
Why?
|
| Sports Nutritional Physiological Phenomena | 1 | 2025 | 2 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 1735 | 0.060 |
Why?
|
| Electric Impedance | 4 | 2001 | 68 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3843 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2014 | 3690 | 0.060 |
Why?
|
| Thoracotomy | 1 | 2006 | 113 | 0.060 |
Why?
|
| Homosexuality, Male | 1 | 2005 | 72 | 0.060 |
Why?
|
| Fluorouracil | 2 | 2016 | 141 | 0.060 |
Why?
|
| Lactase | 1 | 2005 | 41 | 0.060 |
Why?
|
| Indians, North American | 2 | 1997 | 65 | 0.060 |
Why?
|
| Syphilis | 1 | 2005 | 98 | 0.060 |
Why?
|
| Radiodermatitis | 1 | 2004 | 8 | 0.060 |
Why?
|
| Leptin | 3 | 2015 | 225 | 0.060 |
Why?
|
| Calcium | 1 | 2009 | 1146 | 0.060 |
Why?
|
| Bicarbonates | 6 | 1991 | 100 | 0.060 |
Why?
|
| Femur Neck | 1 | 2004 | 15 | 0.060 |
Why?
|
| Hematologic Tests | 1 | 2023 | 37 | 0.050 |
Why?
|
| Workflow | 1 | 2024 | 133 | 0.050 |
Why?
|
| San Francisco | 1 | 2003 | 18 | 0.050 |
Why?
|
| Postpartum Period | 3 | 2018 | 226 | 0.050 |
Why?
|
| Hip Joint | 1 | 2004 | 46 | 0.050 |
Why?
|
| Swine | 3 | 1993 | 1216 | 0.050 |
Why?
|
| Femur | 1 | 2004 | 74 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2023 | 27 | 0.050 |
Why?
|
| Monte Carlo Method | 1 | 2024 | 100 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2005 | 330 | 0.050 |
Why?
|
| Lumbar Vertebrae | 1 | 2004 | 117 | 0.050 |
Why?
|
| Spine | 1 | 2004 | 145 | 0.050 |
Why?
|
| Pain, Postoperative | 1 | 2006 | 274 | 0.050 |
Why?
|
| Actigraphy | 2 | 2014 | 47 | 0.050 |
Why?
|
| Standard of Care | 1 | 2023 | 136 | 0.050 |
Why?
|
| Pelvis | 1 | 2023 | 73 | 0.050 |
Why?
|
| Humidity | 1 | 2022 | 25 | 0.050 |
Why?
|
| Calorimetry | 3 | 1994 | 63 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2021 | 3639 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2007 | 894 | 0.050 |
Why?
|
| Thinness | 1 | 2003 | 77 | 0.050 |
Why?
|
| HIV-1 | 1 | 2006 | 488 | 0.050 |
Why?
|
| Surgical Flaps | 1 | 2004 | 212 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 3476 | 0.050 |
Why?
|
| Spectrum Analysis | 1 | 2022 | 69 | 0.050 |
Why?
|
| Oxygen Consumption | 4 | 2010 | 318 | 0.050 |
Why?
|
| Sierra Leone | 1 | 2021 | 31 | 0.050 |
Why?
|
| Health Care Rationing | 1 | 2021 | 61 | 0.040 |
Why?
|
| Mammals | 1 | 2022 | 277 | 0.040 |
Why?
|
| Respiration | 3 | 2019 | 125 | 0.040 |
Why?
|
| Health Personnel | 1 | 2005 | 538 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2023 | 395 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2022 | 315 | 0.040 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2000 | 123 | 0.040 |
Why?
|
| Overnutrition | 1 | 2019 | 12 | 0.040 |
Why?
|
| Electron Transport Complex IV | 1 | 1999 | 41 | 0.040 |
Why?
|
| Kinetics | 6 | 1995 | 1354 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 1999 | 90 | 0.040 |
Why?
|
| Education, Nursing | 1 | 2019 | 17 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 1999 | 151 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2005 | 815 | 0.040 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2019 | 39 | 0.040 |
Why?
|
| Sexual Behavior, Animal | 1 | 1999 | 88 | 0.040 |
Why?
|
| Animal Feed | 1 | 1999 | 83 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 1999 | 145 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 2021 | 163 | 0.040 |
Why?
|
| Radiometry | 1 | 2019 | 41 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 2157 | 0.040 |
Why?
|
| Growth | 1 | 1999 | 107 | 0.040 |
Why?
|
| Dietary Fats | 2 | 2017 | 301 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 506 | 0.040 |
Why?
|
| China | 1 | 2019 | 295 | 0.040 |
Why?
|
| Nurses | 1 | 2019 | 74 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2018 | 46 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 132 | 0.040 |
Why?
|
| Muscle, Skeletal | 2 | 2022 | 1054 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 2018 | 58 | 0.040 |
Why?
|
| Breath Tests | 7 | 1991 | 184 | 0.040 |
Why?
|
| Physical Examination | 1 | 1999 | 164 | 0.040 |
Why?
|
| Radiotherapy Setup Errors | 1 | 2018 | 2 | 0.040 |
Why?
|
| Failure to Thrive | 1 | 2018 | 91 | 0.040 |
Why?
|
| Hepatitis C Antibodies | 1 | 2018 | 24 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 76 | 0.040 |
Why?
|
| Lysine | 2 | 1991 | 205 | 0.040 |
Why?
|
| Body Weights and Measures | 1 | 2017 | 45 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2017 | 1255 | 0.040 |
Why?
|
| Hunger | 1 | 2017 | 44 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2018 | 41 | 0.040 |
Why?
|
| Statistics as Topic | 2 | 2012 | 261 | 0.040 |
Why?
|
| Medical Records | 2 | 2012 | 194 | 0.030 |
Why?
|
| Oxidation-Reduction | 3 | 2015 | 465 | 0.030 |
Why?
|
| Uncertainty | 1 | 2018 | 105 | 0.030 |
Why?
|
| Torso | 1 | 2017 | 13 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2015 | 1488 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 454 | 0.030 |
Why?
|
| Time | 1 | 2017 | 100 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2018 | 278 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2017 | 95 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2023 | 875 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2016 | 34 | 0.030 |
Why?
|
| Leucovorin | 1 | 2016 | 54 | 0.030 |
Why?
|
| Esophagus | 1 | 2018 | 233 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 262 | 0.030 |
Why?
|
| Acceleration | 2 | 2012 | 28 | 0.030 |
Why?
|
| Hyperthermia, Induced | 1 | 2016 | 58 | 0.030 |
Why?
|
| Camptothecin | 1 | 2016 | 76 | 0.030 |
Why?
|
| Fructose | 1 | 2016 | 62 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2016 | 79 | 0.030 |
Why?
|
| Body Size | 1 | 2016 | 69 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2015 | 21 | 0.030 |
Why?
|
| Education, Medical | 1 | 2019 | 304 | 0.030 |
Why?
|
| Arizona | 1 | 2015 | 26 | 0.030 |
Why?
|
| Boston | 1 | 2015 | 122 | 0.030 |
Why?
|
| Erythropoietin | 1 | 2016 | 110 | 0.030 |
Why?
|
| Longevity | 1 | 2017 | 158 | 0.030 |
Why?
|
| Mothers | 1 | 2018 | 369 | 0.030 |
Why?
|
| Epirubicin | 1 | 2015 | 7 | 0.030 |
Why?
|
| Absorption | 1 | 1995 | 53 | 0.030 |
Why?
|
| Peptide YY | 1 | 2015 | 19 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 127 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 624 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2015 | 118 | 0.030 |
Why?
|
| Gastrointestinal Hormones | 1 | 2015 | 21 | 0.030 |
Why?
|
| Ergometry | 1 | 1994 | 5 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 178 | 0.030 |
Why?
|
| Intestinal Absorption | 5 | 2005 | 193 | 0.030 |
Why?
|
| Methylation | 1 | 2015 | 231 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 248 | 0.030 |
Why?
|
| Blood Glucose | 1 | 1999 | 1195 | 0.030 |
Why?
|
| Taxoids | 1 | 2015 | 72 | 0.030 |
Why?
|
| Remission Induction | 1 | 2015 | 308 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1906 | 0.030 |
Why?
|
| Gene Library | 1 | 2015 | 225 | 0.030 |
Why?
|
| Global Health | 1 | 2019 | 619 | 0.030 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2014 | 18 | 0.030 |
Why?
|
| Physical Exertion | 2 | 2010 | 77 | 0.030 |
Why?
|
| Adipokines | 1 | 2015 | 72 | 0.030 |
Why?
|
| Nutrition Assessment | 1 | 2015 | 139 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2014 | 74 | 0.030 |
Why?
|
| Rats | 2 | 2000 | 3878 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2014 | 53 | 0.030 |
Why?
|
| Decision Trees | 1 | 2014 | 52 | 0.030 |
Why?
|
| Lipids | 1 | 2017 | 568 | 0.030 |
Why?
|
| Erythrocytes | 1 | 1995 | 236 | 0.030 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 1994 | 19 | 0.030 |
Why?
|
| Monitoring, Ambulatory | 1 | 2014 | 57 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 712 | 0.030 |
Why?
|
| Cholesterol, HDL | 2 | 2012 | 394 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2014 | 144 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 401 | 0.030 |
Why?
|
| Potassium | 2 | 2007 | 289 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2019 | 795 | 0.030 |
Why?
|
| Physicians | 1 | 2019 | 630 | 0.030 |
Why?
|
| Heart | 1 | 2018 | 756 | 0.030 |
Why?
|
| Triglycerides | 2 | 2012 | 613 | 0.030 |
Why?
|
| Models, Cardiovascular | 1 | 2014 | 190 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 417 | 0.020 |
Why?
|
| Selection, Genetic | 1 | 1993 | 168 | 0.020 |
Why?
|
| Glycemic Index | 1 | 2012 | 20 | 0.020 |
Why?
|
| Lactation Disorders | 1 | 1992 | 3 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2014 | 181 | 0.020 |
Why?
|
| Anticholesteremic Agents | 1 | 1995 | 245 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2012 | 53 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1146 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 2012 | 242 | 0.020 |
Why?
|
| Chemistry | 1 | 1991 | 61 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1991 | 88 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 330 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2015 | 834 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2015 | 789 | 0.020 |
Why?
|
| Anions | 1 | 1989 | 18 | 0.020 |
Why?
|
| Swine, Miniature | 1 | 1989 | 53 | 0.020 |
Why?
|
| Administration, Oral | 3 | 2006 | 730 | 0.020 |
Why?
|
| Equipment Design | 2 | 2006 | 612 | 0.020 |
Why?
|
| Wakefulness | 1 | 2010 | 103 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 1834 | 0.020 |
Why?
|
| Metabolic Syndrome | 1 | 2012 | 366 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2021 | 3228 | 0.020 |
Why?
|
| Flour | 1 | 2007 | 7 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 3748 | 0.020 |
Why?
|
| Microchemistry | 1 | 1987 | 7 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 2 | 1984 | 261 | 0.020 |
Why?
|
| Physical Endurance | 1 | 2007 | 51 | 0.020 |
Why?
|
| Oxygen Radioisotopes | 1 | 1987 | 4 | 0.020 |
Why?
|
| Guanidine | 1 | 1987 | 10 | 0.020 |
Why?
|
| Zea mays | 1 | 2007 | 44 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2012 | 685 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 1612 | 0.020 |
Why?
|
| Food, Fortified | 1 | 2007 | 98 | 0.020 |
Why?
|
| Muscle Strength | 1 | 2007 | 99 | 0.020 |
Why?
|
| Bottle Feeding | 1 | 2006 | 37 | 0.020 |
Why?
|
| Glucans | 1 | 1986 | 16 | 0.020 |
Why?
|
| Dextropropoxyphene | 1 | 2006 | 3 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2006 | 179 | 0.020 |
Why?
|
| HIV Seroprevalence | 1 | 2006 | 9 | 0.020 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2006 | 17 | 0.020 |
Why?
|
| HIV Seronegativity | 1 | 2006 | 30 | 0.020 |
Why?
|
| Narcotics | 1 | 2006 | 64 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 1989 | 1045 | 0.020 |
Why?
|
| Spectrophotometry, Infrared | 1 | 1985 | 26 | 0.020 |
Why?
|
| Morphine | 1 | 2006 | 86 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 1985 | 52 | 0.020 |
Why?
|
| California | 1 | 2006 | 142 | 0.020 |
Why?
|
| Malawi | 1 | 2007 | 423 | 0.020 |
Why?
|
| Infant Formula | 1 | 2006 | 100 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2006 | 165 | 0.020 |
Why?
|
| Aminopyrine | 1 | 1985 | 7 | 0.020 |
Why?
|
| Fatty Acids, Volatile | 1 | 1985 | 47 | 0.020 |
Why?
|
| Intestine, Small | 2 | 2005 | 317 | 0.010 |
Why?
|
| Lactose Intolerance | 1 | 2005 | 12 | 0.010 |
Why?
|
| Registries | 1 | 2012 | 1562 | 0.010 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2006 | 79 | 0.010 |
Why?
|
| Preventive Health Services | 1 | 2005 | 61 | 0.010 |
Why?
|
| Acetaminophen | 1 | 2006 | 100 | 0.010 |
Why?
|
| Digestion | 1 | 2005 | 43 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 2006 | 148 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2006 | 362 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2007 | 307 | 0.010 |
Why?
|
| Glucose | 2 | 1986 | 923 | 0.010 |
Why?
|
| Methods | 1 | 2003 | 144 | 0.010 |
Why?
|
| Perfusion | 1 | 2005 | 214 | 0.010 |
Why?
|
| Edible Grain | 1 | 1983 | 48 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2004 | 351 | 0.010 |
Why?
|
| Feces | 2 | 1983 | 787 | 0.010 |
Why?
|
| Skin | 1 | 2004 | 551 | 0.010 |
Why?
|
| Acute Disease | 1 | 2004 | 1187 | 0.010 |
Why?
|
| Paracoccus denitrificans | 1 | 1999 | 1 | 0.010 |
Why?
|
| Cattle | 1 | 1999 | 588 | 0.010 |
Why?
|
| Leucine | 1 | 1996 | 313 | 0.010 |
Why?
|
| Child Development | 1 | 1997 | 287 | 0.010 |
Why?
|
| Rest | 1 | 1994 | 66 | 0.010 |
Why?
|
| Sodium Bicarbonate | 2 | 1985 | 58 | 0.010 |
Why?
|
| Cholesterol, Dietary | 1 | 1994 | 48 | 0.010 |
Why?
|
| Plant Preparations | 1 | 1994 | 18 | 0.010 |
Why?
|
| Weaning | 1 | 1993 | 49 | 0.010 |
Why?
|
| Exercise Test | 1 | 1994 | 268 | 0.010 |
Why?
|
| Milk | 1 | 1994 | 126 | 0.010 |
Why?
|
| Body Constitution | 1 | 1992 | 42 | 0.010 |
Why?
|
| Mexico | 1 | 1992 | 190 | 0.010 |
Why?
|
| Estrogens | 1 | 1994 | 522 | 0.010 |
Why?
|
| Radioisotope Dilution Technique | 1 | 1988 | 43 | 0.000 |
Why?
|
| Electromagnetic Phenomena | 1 | 1986 | 4 | 0.000 |
Why?
|
| Oligosaccharides | 1 | 1986 | 78 | 0.000 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 1985 | 11 | 0.000 |
Why?
|
| Acetates | 1 | 1985 | 79 | 0.000 |
Why?
|
| Structure-Activity Relationship | 1 | 1986 | 612 | 0.000 |
Why?
|
| Infusions, Parenteral | 1 | 1984 | 100 | 0.000 |
Why?
|
| Random Allocation | 1 | 1985 | 451 | 0.000 |
Why?
|
| Rabbits | 1 | 1985 | 736 | 0.000 |
Why?
|
| Nutrition Disorders | 1 | 1984 | 32 | 0.000 |
Why?
|
| Sodium | 1 | 1985 | 307 | 0.000 |
Why?
|
| Colon | 1 | 1983 | 381 | 0.000 |
Why?
|